36 completed, 21 recruiting, 17 active not recruiting, 9 unknown. 39 Phase 2, 23 Phase 1, 22 Not applicable, 7 Phase 3, 3 Early Phase 1.
Follow Endometrial Carcinoma: new trials by email Literature Review of Endometrial Carcinoma trials Research Report on Endometrial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain Biospecimen Collection, Low-Dose Aspirin, Patient Observation - Endometrial Carcinoma | Phase 4 | Not yet recruiting | Mayo Clinic | 20 | 2027-02-12 | 2026-08-05 |
| Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer Dostarlimab, Carboplatin and paclitaxel - Endometrial Carcinoma, Neoplasms, Endometrial | Phase 3 | Not yet recruiting | GlaxoSmithKline | 378 | 2026-11-12 | 2026-10-19 |
| Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial Aerobic Exercise, Biospecimen Collection, Dietary Intervention - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Not applicable | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 90 | 2026-10-10 | 2026-07-23 |
| A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer Best Practice, Interview, Supportive Care - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Not applicable | Recruiting | City of Hope Medical Center | 126 | 2026-09-09 | 2026-10-16 |
| Flyte Device for Improving Urinary Incontinence Among Endometrial and Cervical Cancer Survivors Who Have Undergone Radiation Therapy Educational Intervention, Interview, Flyte Medical Device Usage and Evaluation - Cervical Carcinoma, Endometrial Carcinoma | Not applicable | Recruiting | Mayo Clinic | 44 | 2026-08-20 | 2026-08-31 |
| Elemene Liposomes in Endometrial Cancer Elemene Injection/Elemene Oral Emulsion, Carboplatin-Paclitaxel chemotherapy - Endometrial Carcinoma | Phase 2 | Not yet recruiting | Women's Hospital School Of Medicine Zhejiang University | 212 | 2026-08-01 | 2026-07-31 |
| Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer Behavioral Intervention, Educational Intervention, Internet-Based Intervention - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Not applicable | Withdrawn | City of Hope Medical Center | 2026-07-16 | 2026-02-04 | |
| Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer Non-Interventional Study - Endometrial Carcinoma | Recruiting | Mayo Clinic | 25 | 2026-06-10 | 2026-07-09 | |
| GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine - Endometrial Carcinoma, Endometrial Carcinoma Stage III | Early Phase 1 | Enrolling by invitation | Biogenea Pharmaceuticals Ltd. | 40 | 2026-02-02 | 2026-01-07 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases. Ovarian Carcinoma, Cervical Carcinoma | Not yet recruiting | National Cancer Institute, Naples | 130 | 2025-12-01 | 2025-12-05 | |
| FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors FT836, Cetuximab, Trastuzumab - Non-Small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Recruiting | Fate Therapeutics | 119 | 2025-11-04 | 2026-09-02 |
| AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer Bemarituzumab, Bevacizumab - Endometrial Carcinoma, Ovarian Cancer | Phase 1 / Phase 2 | Withdrawn | Centre Leon Berard | 2025-10-15 | 2026-04-23 | |
| Molecular and ctDNA Characterization of High-Risk Endometrial Cancer Non-Interventional Study - Endometrial Carcinoma, Endometrial High Grade Endometrioid Adenocarcinoma | Recruiting | Mayo Clinic | 100 | 2025-10-01 | 2026-04-13 | |
| Screening and Staging of Benign vs Malignant Pelvic Abnormalities Non-Interventional Study - Endometrial Carcinoma, Prostate Carcinoma | Recruiting | Mayo Clinic | 60 | 2025-09-04 | 2026-02-17 | |
| Patient Journey in Advanced Gynecologic Cancers interview - Genital Neoplasms, Female, Uterine Cervical Neoplasms | Not yet recruiting | Tongji Hospital | 780 | 2025-07-01 | 2025-06-11 | |
| An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study Behavioral Intervention, Best Practice, Biospecimen Collection - Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | Not applicable | Recruiting | Roswell Park Cancer Institute | 120 | 2025-06-04 | 2026-01-06 |
| Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of Gynecology and Obestetrics (FIGO) Endometrial cancer (EC) - Clinicopathological, Endometrial Carcinoma | Recruiting | Assiut University | 110 | 2024-10-10 | 2024-10-15 | |
| First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer Nesuparib, Pembrolizumab - Endometrial Cancer, Recurrent Endometrial Carcinoma | Phase 2 | Recruiting | Yonsei University | 92 | 2024-09-12 | 2025-04-03 |
| Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma Paclitaxel/epirubcin/carboplatin, Paclitaxel/carboplatin - Endometrial Carcinoma | Not applicable | Completed | Sohag University | 60 | 2024-08-15 | 2026-05-22 |
Showing 20 of 101. Sign in to see all of them.
Endometrial Neoplasms (101) · Uterine Cervical Neoplasms (28) · Ovarian Neoplasms (23) · Melanoma (13) · Breast Neoplasms (11) · Carcinoma, Renal Cell (11) · Colorectal Neoplasms (11) · Stomach Neoplasms (11) · Triple Negative Breast Neoplasms (11) · Carcinoma, Non-Small-Cell Lung (10) · Carcinoma, Hepatocellular (9) · Carcinoma, Transitional Cell (9) · Fallopian Tube Neoplasms (9) · Squamous Cell Carcinoma of Head and Neck (9) · Prostatic Neoplasms (8)
Female Urogenital Diseases (101) · Female Urogenital Diseases and Pregnancy Complications (101) · Genital Diseases (101) · Genital Diseases, Female (101) · Neoplasms by Site (101) · Urogenital Diseases (101) · Urogenital Neoplasms (101) · Uterine Diseases (101) · Genital Neoplasms, Female (98) · Uterine Neoplasms (96) · Neoplasms (94) · Endocrine Gland Neoplasms (31) · Endocrine System Diseases (31) · Adnexal Diseases (29) · Gonadal Disorders (28)
Carboplatin (10) · Paclitaxel (10) · pembrolizumab (9) · Specimen Handling (7) · Interviews as Topic (5) · Megestrol Acetate (5) · Bevacizumab (3) · Counseling (3) · Early Intervention, Educational (3) · Methods (3) · Nivolumab (3) · Palliative Care (3) · Radiation (3) · Standard of Care (3) · Taxes (3)
Mayo Clinic (11) · National Cancer Institute (NCI) (6) · M.D. Anderson Cancer Center (5) · Ohio State University Comprehensive Cancer Center (5) · Centre Leon Berard (3) · City of Hope Medical Center (3) · Memorial Sloan Kettering Cancer Center (3) · Xencor, Inc. (3) · Dana-Farber Cancer Institute (2) · ARCAGY/ GINECO GROUP (1) · Advenchen Laboratories, LLC (1) · Assiut University (1) · AstraZeneca (1) · Azienda USL Reggio Emilia - IRCCS (1) · Biogenea Pharmaceuticals Ltd. (1)
United States (65) · China (11) · France (9) · Italy (6) · South Korea (6) · Spain (6) · Germany (5) · Belgium (3) · Canada (3) · Switzerland (3) · Australia (2) · Egypt (2) · Puerto Rico (2) · Turkey (Türkiye) (2) · United Kingdom (2)
Anne Reb (2) · Britt K Erickson (2) · Jose A Rauh-Hain (2) · Shariska Harrington, MD (2) · Akila Viswanathan, MD, MPH (1) · Alessandro D. Santin, M.D. (1) · Allison E. Garda, M.D. (1) · Allison Quick, MD (1) · Amit Oza, MD (1) · Antonio Llombart, MD, PhD (1) · Arash Yavari, MBBS (1) · Benjamin Oshrine (1) · Benjamin Thompson, MD, PhD (1) · Brian Focht, PhD, FACSM (1)
PMID 25199746, PMID 26394736, PMID 26586415, PMID 28275119, PMID 28950327, PMID 29290809, PMID 29551477, PMID 29935649, PMID 30943124, PMID 31325591, PMID 31400383, PMID 31682550, PMID 31822399, PMID 31980466, PMID 32359091, PMID 32463741, PMID 32919526, PMID 33048619, PMID 33358206, PMID 33433743, PMID 33836153, PMID 34103352, PMID 34470826, PMID 34990208, PMID 35114169, PMID 35133871, PMID 35138919, PMID 35230489, PMID 35361487, PMID 35443252, PMID 35551299, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36351402, PMID 36450938, PMID 36493574, PMID 36675280, PMID 36748723, PMID 37053535, PMID 37131154, PMID 37185961, PMID 37322121, PMID 37532929, PMID 37934000, PMID 38591867, PMID 38653864, PMID 38721402, PMID 39666929
2015 (3), P30CA033572 (3), R21CA293326 (2), U10CA180868 (2), 2016 (1), 2023 (1), 2025 (1), N01CM00100 (1), N01CN00033 (1), P30CA014520 (1), P30CA015083 (1), P30CA042014 (1), P30CA047904 (1), P30CA060553 (1), P30CA072720 (1)